These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21513501)

  • 61. Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin.
    Kotecki N; Penel N
    Curr Opin Oncol; 2016 Sep; 28(5):437-40. PubMed ID: 27428364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gastric cancer management: Kinases as a target therapy.
    Farran B; Müller S; Montenegro RC
    Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):613-622. PubMed ID: 28271563
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors.
    Jenardhanan P; Panneerselvam M; Mathur PP
    Curr Top Med Chem; 2019; 19(6):467-485. PubMed ID: 31184298
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Natural products as a source of protein kinase activators and inhibitors.
    Marston A
    Curr Top Med Chem; 2011; 11(11):1333-9. PubMed ID: 21513498
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Progress and potential impact of RET kinase targeting in cancer.
    Mulligan LM
    Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
    [No Abstract]   [Full Text] [Related]  

  • 67. Compounds from Natural Sources as Protein Kinase Inhibitors.
    Baier A; Szyszka R
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33198400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 69. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular Pathways: Targeting ATR in Cancer Therapy.
    Karnitz LM; Zou L
    Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches.
    Wang Y; Ji QS; Mulvihill M; Pachter JA
    Recent Results Cancer Res; 2007; 172():59-76. PubMed ID: 17607936
    [No Abstract]   [Full Text] [Related]  

  • 72. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Kinase inhibitor conjugates.
    Harmsen S; Kok RJ
    Curr Pharm Des; 2012; 18(20):2891-900. PubMed ID: 22571658
    [TBL] [Abstract][Full Text] [Related]  

  • 74. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of kinase activity using versatile fluorescence quencher probes.
    Rhee HW; Lee SH; Shin IS; Choi SJ; Park HH; Han K; Park TH; Hong JI
    Angew Chem Int Ed Engl; 2010 Jul; 49(29):4919-23. PubMed ID: 20540130
    [No Abstract]   [Full Text] [Related]  

  • 76. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Kinase targets in CNS drug discovery.
    Gunosewoyo H; Yu L; Munoz L; Kassiou M
    Future Med Chem; 2017 Mar; 9(3):303-314. PubMed ID: 28176536
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
    Heffron TP
    J Med Chem; 2016 Nov; 59(22):10030-10066. PubMed ID: 27414067
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ROS1 Kinase Inhibitors for Molecular-Targeted Therapies.
    Al-Sanea MM; Abdelazem AZ; Park BS; Yoo KH; Sim T; Kwon YJ; Lee SH
    Curr Med Chem; 2016; 23(2):142-60. PubMed ID: 26438251
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.
    Gazzard L; Williams K; Chen H; Axford L; Blackwood E; Burton B; Chapman K; Crackett P; Drobnick J; Ellwood C; Epler J; Flagella M; Gancia E; Gill M; Goodacre S; Halladay J; Hewitt J; Hunt H; Kintz S; Lyssikatos J; Macleod C; Major S; Médard G; Narukulla R; Ramiscal J; Schmidt S; Seward E; Wiesmann C; Wu P; Yee S; Yen I; Malek S
    J Med Chem; 2015 Jun; 58(12):5053-74. PubMed ID: 25988399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.